Quick Answer
Xilio Therapeutics, Inc. reported Earnings Per Share Diluted of $4.19 (loss) per share for the year ending 2025.
- Xilio Therapeutics, Inc. showed an increase of +72.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Xilio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $24.19 (loss) per share | Q1 2021: $23.53 (loss) per share | Q2 2021: $31.48 (loss) per share | Q3 2021: $21.27 (loss) per share | Q1 2022: $0.78 (loss) per share | Q2 2022: $0.90 (loss) per share | Q3 2022: $0.72 (loss) per share | Q1 2023: $0.83 (loss) per share | Q2 2023: $0.70 (loss) per share | Q3 2023: $0.61 (loss) per share | Q1 2024: $0.62 (loss) per share | Q2 2024: $0.24 (loss) per share | Q3 2024: $0.22 (loss) per share | Q1 2025: $0.18 (loss) per share | Q2 2025: $0.16 (loss) per share | Q3 2025: $0.11 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Xilio Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 96.0%.
- Historical annual values: Fiscal year 2025: $4.19 (loss) per share | Fiscal year 2024: $15.24 (loss) per share | Fiscal year 2023: $2.78 (loss) per share | Fiscal year 2022: $3.22 (loss) per share | Fiscal year 2021: $13.52 (loss) per share | Fiscal year 2020: $105.42 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: